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Veterinary Hospital Dissemination of CTX-M-15
Extended-Spectrum Beta-Lactamase–Producing
Escherichia coli ST410 in the United Kingdom
Dorina Timofte,1–3 Iuliana Elena Maciuca,1 Nicola J. Williams,4 Andrew Wattret,1 and Vanessa Schmidt1,2
We characterized extended-spectrum beta-lactamases (ESBLs) and plasmid-mediated quinolone resistance
(PMQR) in 32 Escherichia coli extended spectrum cephalosporin (ESC)-resistant clinical isolates from UK
companion animals from several clinics. In addition, to investigate the possible dissemination of ESBL clinical
isolates within a veterinary hospital, two ESBL-producing E. coli isolates from a dog with septic peritonitis and a
cluster of environmental ESC-resistant E. coli isolates obtained from the same clinic and during the same time
period, as these two particular ESBL-positive clinical isolates, were also included in the study. Molecular char-
acterization identified blaCTX-M to be the most prevalent gene in ESC-resistant isolates, where 66% and 27% of
clinical isolates carried blaCTX-M-15 and blaCTX-M-14, respectively. The only PMQR gene detected was aac(6’)-
Ib-cr, being found in 34% of the ESC E. coli isolates and was associated with the carriage of blaCTX-M-15. The
clinical and environmental isolates investigated for hospital dissemination had a common ESBL/AmpC phenotype,
carried blaCTX-M-15, and co-harbored blaOXA-1, blaTEM-1, blaCMY-2, and aac(6’)-Ib-cr. Multilocus sequence typing
identified them all as ST410, while pulse-field gel electrophoresis demonstrated 100% homology of clinical and
environmental isolates, suggesting hospital environmental dissemination of CTX-M-15–producing E. coli ST410.
Keywords: E. coli, ESBL, surveillance, veterinary, infection control
Introduction
Escherichia coli are opportunistic pathogens in hu-mans and companion animals and can be associated
with a variety of extraintestinal infections, which may re-
quire antimicrobial therapy.1 Increased use of antimicrobials
in companion animals may select for antimicrobial-resistant
bacteria, and concerns have been raised that these host
species may act as potential reservoirs for human infec-
tions.2 Particularly concerning for both human and veteri-
nary health is the increasing resistance to extended spectrum
cephalosporins (ESCs) through the production of extended-
spectrum beta-lactamases (ESBLs).3–6 There is increasing
evidence that E. coli-producing ESBL and/or AmpC beta-
lactamases are emerging in companion animals,7,8 setting
new challenges for veterinary practitioners due to thera-
peutic and infection control implications.
Several studies have described the prevalence of ESBL
resistance in bacteria from companion animals,3,4,9–11 but the
role that these animals may play in the spread of such resistant
bacteria or determinants, is not yet fully determined. Previous
molecular studies have shown that, in human hospital settings,
ESBL genetic determinants have the potential to spread either
through clonal dissemination or plasmid transfer, posing a
serious threat to patient care and safety.6,12 The development
of large veterinary hospitals with intensive care facilities has
created similar conditions for the emergence of animal hos-
pital acquired infections and a few studies have shown the
association of multidrug resistant (MDR) organisms, such as
E. coli, Acinetobacter baumannii, Enterobacter spp., and
Enterococcus spp., with animal nosocomial infections.13–19
However, with the exception of a few recent studies showing
the hospital acquisition and/or dissemination of beta-
lactamases or ESBL-producing Klebsiella pneumoniae and
A. baumannii20–23 and compared with the wealth of data from
human medicine, there is a paucity of studies investigating the
potential of ESBL-producing E. coli to spread and cause
nosocomial infections in veterinary clinics or hospital settings.
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The aim of this study was dual; first, to characterize ESBL
and plasmid-mediated quinolone resistance (PMQR) genes in
E. coli from clinical specimens submitted for routine bacterial
culture to the Veterinary Microbiology Diagnostics labora-
tory in the Liverpool School of Veterinary Science. Second,
to analyze and compare a cluster of clinical and environ-
mental ESBL-producing E. coli obtained from a UK Veter-
inary Hospital to identify the potential of clinical isolates to
spread within such environments.
Materials and Methods
Bacterial isolates
All E. coli isolates were obtained from companion animal
clinical specimens submitted from a veterinary hospital and a
number of small veterinary clinics and collected for this study
between January 2010 and November 2011. Clinical speci-
mens were plated out aerobically on 5% sheep blood agar
(Oxoid) and incubated for 24 hours at 37C. Clinical isolates
presumptively identified as E. coli based on a positive reac-
tion on Eosin Methylene Blue Agar (EMBA; Oxoid, Ba-
singstoke, UK) and which showed reduced susceptibility to
cefpodoxime (10mg) and/or cefoxitin (30mg), used as indi-
cators for ESBL and AmpC production, were selected for this
study. In addition, samples from active bacterial environ-
mental surveillance, which is also offered for veterinary
hospitals as part of the Diagnostic Service, are also processed
by the laboratory, and a cluster of hospital environmental
E. coli isolates was also included in this study. Detection of
resistance to ESC in environmental E. coli isolates followed
the same protocols as for clinical isolates. The identification
of clinical and environmental isolates was performed using
API 20E Identification Kits (bioMerieux, France) and also by
PCR detection of the uidA gene for confirmation of E. coli.24
Antimicrobial susceptibility testing
Susceptibility testing was performed by disc diffusion to
representatives of beta-lactam and non-beta-lactam antimi-
crobial classes on ISO-Sensitest agar (Oxoid, Basingstoke,
UK) and results were interpreted according to the BSAC
(British Society for Antimicrobial Chemotherapy) interpreta-
tive criteria.25 E. coli ATCC 25922 was used as control strain.
All isolateswere tested for ESBL production by the double disc
synergy test (DDST).26
Characterization of ESBL and other resistance genes
Cell lysates obtained from all investigated isolates were
screened by PCR and DNA sequencing for the presence of
blaCTX-M, blaSHV, blaTEM, blaOXA, plasmid-mediated blaAmpC
variants, PMQR genes qnrA, B, S, as well as the cr variant of
aac(6’)-Ib, as previously described.
27–31 Specific PCR as-
says were performed to identify the possible association of
blaCTX-M-15 with ISEcp1 or IS26 insertion elements, which
have been shown to be involved in the mobilization and
expression of blaCTX-M genes.
32,33
Resistance transfer and PCR-based replicon typing
To determine the transferability of the ESBL and PMQR
genes, conjugation by plate mating was performed with
streptomycin-resistant E. coli HB101as the recipient and se-
ven selected donors harboring blaCTX-M-15 (n=6) or blaCTX-M-14
(n= 1). Plasmid replicons involved in the transfer of the re-
sistance genes were analyzed by PCR-based plasmid replicon
typing (PBRT) as described by Carattoli et al.34
Molecular characterization of isolates
A multiplex PCR described by Clemont et al.,35 was used
to assign the E. coli isolates to a phylogenetic group. Genetic
relatedness of isolates identified to carry blaCTX-M genes was
analyzed by macrorestriction pulsed-field gel electrophoresis
(PFGE) (www.cdc.gov/pulsenet/pathogens/). Data were ana-
lyzed using BioNumerics software version 5.1 (Applied
Maths). A tolerance of 1.00% was selected and cluster anal-
ysis of PFGE pulsotypes was performed by the unweighted
pair group method with average linkages (UPGMA), using
the Dice coefficient to analyze similarities and define pulso-
types. PFGE pulsotypes were identified as isolates with ‡90%
similarity. Multilocus sequence typing (MLST) was per-
formed as previously described36 for at least one isolate from
each identified PFGE cluster.
Results
Bacterial isolates and antimicrobial
susceptibility testing
Four hundred and forty five E. coli isolates (n = 445) were
obtained from companion animal clinical specimens be-
tween January 2010 and November 2011, of which 32 (7%)
cefpodoxime and/or cefoxitin-resistant nonduplicate isolates
(30 canine and two feline) were characterized in this study.
The selected isolates were both from normally sterile sites
[urine (n= 6), liver/bile (n = 4), abdominal fluid (n = 3),
bronchoalveolar lavage (n= 1), lymph-node biopsy (n = 1)]
and also from sites colonized with normal flora and where
cultures yielded mixed bacterial growth [colon biopsies
(n = 3), wounds (n = 4), skin/ear swabs (n= 5), fecal samples
(n = 5)]. In addition, a cluster of environmental ESC-
resistant E. coli isolates (n = 6) obtained from the same
clinic and during the same time period as two particular
ESBL-positive clinical isolates, was also included in the
study and characterized by the same methods as the clinical
isolates. These two ESBL-positive clinical isolates were
from the same dog, which had been admitted with septic
peritonitis following duodenal ulceration; one isolate was
obtained from abdominal fluid (12L-0659) and one from a
surgical site wound swab (12L-0671) following surgery.
The environmental ESC-resistant E. coli isolates were ob-
tained from the ultrasound table (EBM-111) where the dog
was examined and also from various areas of the ward
where the dog was hospitalized; these included the kennel
area, the drip pump attached to the kennel, the ward door
handle, the ward fridge handle, and the ward computer
keyboard (EBM-114, EBM-115, EBM-116, EBM-118, and
EBM-119).
All isolates characterized in this study showed resistance
to ampicillin, amoxicillin–clavulanic acid (CV), cefotaxime,
cefpodoxime, ceftazidime, and tetracycline. In addition,
71% of isolates exhibited resistance to cefoxitin, 65% to
ciprofloxacin, and 59% to trimethoprim/sulfamethoxazole
(Table 1). Interestingly, 29% of isolates showed resistance
to amoxicillin-clavulanic acid, but susceptibility to cefoxitin.
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This may indicate that mechanisms such as those which
involve combinations blaCTX-M-15 and blaOXA-1 genes (as
seen in isolates 10L-4543, 11L-1298, 10L-2646) may give
rise to this phenotype. Other mechanisms responsible for
amoxicillin-clavulanic acid resistance, but which do not
normally confer resistance to the cephamycins includes
hyperproduction of TEM-1 or SHV-1 beta-lactamases.
Although we did not attempt to determine whether this was
the case, a number of the tested isolates carried blaTEM-1b
only and were fully susceptible to cefoxitin (10L-1747, 10L-
2253, 11L-2520, Table 1).
The eight E. coli isolates included in this study for
comparison (two clinical and six environmental) were pro-
cessed in the diagnostic laboratory simultaneously and the
identical susceptibility phenotypes identified in this group of
isolates triggered closer investigation. In the DDST, they
showed no synergy for ceftazidime and cefotaxime with CV
combinations, while only a small zone of inhibition (less
than 4mm) appeared for the cefpodoxime/CV combination.
All isolates were resistant to cefoxitin and this raised the
possibility of the ESBL phenotype being masked by the
additional presence of AmpC cephalosporinase, which is not
inhibited by CV; additional testing with a cefepime/CV
combination revealed the presence of ESBL phenotypes in
these eight clinical/environmental E. coli isolates.
Characterization of ESBL and other resistance genes
Among the ESC-resistant clinical E. coli isolates, CTX-M
type ESBL was the most prevalent, found in 56% (18/32) of
isolates, of which 66% (12/18) of isolates harbored blaCTX-M-15,
with blaCTX-M-14 being found in five isolates (27%) and
blaCTX-M-27 identified in one isolate. With the exception of
one isolate, which carried blaCTX-M-15 alone, the remaining
ESC-resistant clinical E. coli isolates also carried blaTEM-1,
blaCMY-2, and/or blaOXA-1 in various combinations
(Table 1). The aac(6’)-Ib-cr gene was the only PMQR
gene detected, although at high prevalence (34.3%), and was
associated with the carriage of blaCTX-M-15. The eight clin-
ical and environmental isolates that showed the common
ESBL/AmpC phenotype, carried blaCTX-M-15 and also co-
harbored blaOXA-1, blaTEM-1, blaCMY-2, and aac(6’)-Ib-cr.
Specific PCR assays revealed that ISEcp1 or IS26, or in
some isolates ISEcp1 disrupted by IS26, was associated with
blaCTX-M-15 (Table 1). In addition, ISEcp1was associated
with blaCTX-M-14 in one of the five isolates and was not
found to be associated with blaCTX-M-27, findings which
support the diversity of the CTX-M genetic arrangements in
E. coli isolates resulting from various mobilization events.
Resistance transfer and PBRT
Five transconjugants (four blaCTX-M-15 and one blaCTX-M-14),
for which the ESBL phenotype and the presence of blaCTX-
M-14/15 was confirmed, were generated on nutrient agar
supplemented with cefotaxime (1mg/L) and streptomycin
(50mg/L). PBRT showed that the transfer of blaCTX-M-15
was mainly associated with the FIA (n = 4), FIB (n = 4),
IncI1 (n= 3), Y (n= 2), and B/O (n = 1) replicon types, while
IncY type replicon was associated with the transfer of
blaCTX-M-14. PCR also showed that blaTEM-1, blaCMY-2,
blaOXA-1, as well as aac(6’)-Ib-cr, had cotransferred with the
blaCTX-M-14/15 in all transconjugants, indicating that they are
located on conjugative plasmids.
Molecular typing of isolates
Phylogenetic typing identified that 63% of E. coli isolates
belonged to phylogenetic group A and the remaining iso-
lates were typed to the more potentially pathogenic groups,
B2 (21%) or group D (15%). PFGE showed clonal diversity
of the CTX-M-positive isolates and five pulsotypes (PT 1, 2,
4, 6, and 7) were identified with similarity of isolates greater
than 90% (Fig. 1). The main group (PT 4, n= 9) included the
eight clinical and environmental isolates with the common
ESBL/AmpC phenotype and interestingly, another clinical
isolate from a colon biopsy obtained from a dog (11L-2603),
which was admitted with diarrhea in the same clinic 7
months previously. The second main cluster (PT 6) was
formed by three isolates identified to belong to the human
pandemic ST131 by MLST. Interestingly, a fourth member
of this clone, which carried blaCTX-M-27, showed only a 73%
similarity with the ST131 group. MLST also showed that the
clinical and environmental isolates with the common ESBL/
AmpC phenotype belonged to ST410, while the next most
common ST identified in our blaCTX-M isolates was ST617
(Fig. 1).
Discussion
This study characterized a collection of ESC-resistant
E. coli and identified a high prevalence (7%) of ESC-resistant
E. coli in clinical specimens from companion animals in the
UK, which is considerably higher than that found in similar
studies from pets in France (3.7%) or The Netherlands
(2%).3,10 We also found a high prevalence (56%) of CTX-M
type ESBL-producing E. coli from clinical specimens where
66% of clinical ESBL-producing E. coli carried blaCTX-M-15,
which is among the highest reported rates in companion an-
imals. To the best of our knowledge, higher carriage rates of
blaCTX-M-15 in clinical animal isolates have only been re-
ported in the United States where 78% of the ESBL-
producing E. coli clinical isolates from companion animals
were found to carry blaCTX-M-15.
11 In Europe, 46% and 36%
of canine ESBL-producing E. coli isolates (from Germany
and France, respectively) carried blaCTX-M-15.
10,37 In The
Netherlands, Dierikx et al.,3 found that of 29 E. coli isolates
with an ESBL/AmpC phenotype from diseased dogs, cats,
and horses, only five isolates (from dogs) (17%) carried
blaCTX-M-15. In addition, a lower prevalence of blaCTX-M-15
was found in Switzerland, where eight of the 107 E. coli
isolates obtained from canine urine samples (7.4%) were
ESBLs and all carried blaCTX-M-15.
4 Furthermore, only one
E. coli isolate carried this gene in a similar study in Italy and
no blaCTX-M was identified in a study characterizing multidrug-
resistant canine urinary E coli isolates from Scotland.38,39
E. coli carrying blaCTX-M-15 is the most common ESBL
type associated with infections in humans in the United
Kingdom and Europe.6 On this basis, the high prevalence of
veterinary clinical isolates carrying blaCTX-M-15 identified in
this study is worrying both in the context of likely inter-
species transfer (man to animals), as well as previous studies
identifying animals as a potential reservoir of ESBL-
producing E. coli for human infection.40,41 In addition, the
clinical and environmental isolates investigated for hospital
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dissemination had a common ESBL/AmpC phenotype and
genotype and MLST showed that they all belonged to
ST410. PCR analysis also demonstrated that all isolates had
an identical genetic environment of blaCTX-M-15, where an
IS26 element was inserted in between blaCTX-M-15 gene and
its promoter found in ISEcp1. PFGE showed 100% ho-
mology for the two ESBL/AmpC E. coli clinical isolates
from the dog with septic peritonitis and the environmental
isolates obtained from hospital areas with which this patient
came in direct contact (ultrasound table and kennel), or were
likely to have spread through staff contact (door handle, the
ward fridge handle, and the ward computer keyboard).
This study demonstrated veterinary hospital dissemination
of clinical E. coli ST410 isolates co-harboring blaCTX-M-15,
blaTEM-1, OXA-1 or CMY-2, and acc(6‘)-Ib-cr, a genotype con-
ferring MDR and often associated with human clinical iso-
lates.42–44 Following the confirmation of the ESBL/AmpC
phenotype in these isolates, the laboratory contacted the vet-
erinary hospital’s infection control team, which took action by
cleaning and disinfection of the areas/surfaces identified as
sources of these organisms and reinforced hand hygiene policy.
The environmental sampling was repeated after reinforcing
cleaning and disinfection protocols and no E. coli isolates with
an ESBL/AmpC phenotype were identified in the subsequent
bacterial environmental surveillance specimens. This study
demonstrates the role that the microbiology laboratory can play
in the early detection and prevention of MDR isolate dissem-
ination in veterinary hospitals. The presence of multiple b-
lactamases in Gram-negative bacteria may interfere with the
ESBL phenotypic confirmatory tests45,46 and it is therefore
important that veterinary diagnostic microbiology laboratories
are continuously updating their detection methods to recognize
ESBL, AmpC, or other emerging resistance phenotypes and to
translate the therapeutic or epidemiological significance of
these findings to veterinary clinicians. This study also high-
lights the importance of infection control programs and the
benefits of environmental surveillance in the veterinary hos-
pitals for limiting the spread of nosocomial pathogens. Fur-
thermore, the dissemination of the ESBL/AmpC E. coli ST410
isolates from veterinary patients (probably from surgical
wounds) to the environment, as shown in this study, may in-
dicate a pattern of spread that can occur in the community,
especially in the owners home, highlighting the associated
human health risk. Therefore, accurate laboratory detection of
ESBL/AmpC phenotypes can support the veterinary hospitals
in the process of implementing policies for owner’s informa-
tion and infection control advice for limiting the owner’s ex-
posure and associated transmission risks.
Recent EUCAST and CLSI guidelines recommend that
when using the new interpretative breakpoints, routine ESBL
testing is no longer necessary and reporting of susceptibility
results to penicillins and cephalosporins for ESBL-producing
FIG. 1. Dendrogram showing cluster analysis of XbaI PFGE patterns of CTX-M–producing clinical and environmental
(EBM) Escherichia coli isolates. The columns to the right of the PFGE pattern indicate the ID, ST, PG, and identified beta-
lactamases and PMQR genes. PFGE pulsotypes (PT 1–9) were identified as isolates with ‡90% similarity (represented as a
vertical dotted line). ID, isolate identification; ST, sequence type; PG, phylogenetic group; PFGE, pulsed-field gel elec-
trophoresis; PMQR, plasmid-mediated quinolone resistance.
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Enterobacteriaceae should be ‘as found’.47,48 However, these
new guidelines indicate that ESBL screening may still be
useful for epidemiological reasons.47,48 Our findings, dem-
onstrating a high prevalence of CTX-M-15 ESBL–producing
E. coli in clinical specimens from companion animals, as well
as the dissemination of E. coli ST410 through the hospital
environment, support the need for veterinary laboratories to
continue ESBL screening and to continuously upgrade their
expertise in detection of complex antimicrobial resistance
phenotypes, to benefit both human and animal health.
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